Performance of global quality of scale of EORTC QLQ-C30 for measuring quality of life

1579 Words7 Pages
Primary liver cancer is currently the second leading cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is the main form of primary liver cancer accounting 70-85% of total liver cancer burden. Key etiologies include viral infections from hepatitis B and C, and cirrhosis. Since these two viral infections are predominant in Asia and Africa, more than 80% of cases are encountered in these regions [Jemal et al., 2011]. Despite the widespread use of surveillance programs in at-risk populations, 80% of HCC cases are diagnosed with advanced stage, and curative therapies such as surgical resection, transplantation, or radiofrequency ablation are possible in only 20% of the patients [Zhu 2003; Cahill et al., 2004; Sun et al., 2008]. The unresectable cases receive palliative care treatment such as chemotherapy or hormonal therapy which does not aim to cure but instead looks to improve survival and quality of life (QoL).
In palliative cancer patients, control of symptoms and preservation of QoL are two of the most important goals. Symptoms arising from the cancer itself or treatment could greatly affect QoL, thus making it one of the most important outcomes. The Quality of Life Questionnaire (QLQ-C30) of the European Organization for Research and Treatment of Cancer (EORTC) is one of the standard instruments for measuring HRQoL in patients with any type of cancer [Aaronson, et al., 1993]. QLQ-C30 includes symptom scales containing symptoms that affect most of the cancer patients, along with functional scales, such as physical, role, social and emotional well-being. It also has a global QoL scale for overall health and quality of life derived from two of its 30 items [Fayers et al., 2001]. The EORTC does not recommend a...

... middle of paper ...

...tality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:, accessed on 22nd May 2014.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
Oken MM, Creech RH, Tormey DC et-al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-55.
Sprangers, M. A., & Schwartz, C. E. Integrating response shift into health-related quality of life research: A theoretical model. Social Science and Medicine 1999; 48(11):1507–1515.
Trevino KM, Fasciano K, Block S, Prigerson HG. Correlates of social support in young adults with advanced cancer. Support Care Cancer 2013;21(2):421-9.
Zhu AX. Hepatocellular carcinoma: Are we making progress? Cancer Invest 2003;21(3):418–428.

More about Performance of global quality of scale of EORTC QLQ-C30 for measuring quality of life

Open Document